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Abstract
Rationale Depressed patients robustly exhibit affective biases
in emotional processing which are altered by SSRIs and pre-
dict clinical outcome.
Objectives The objective of this study is to investigate wheth-
er psilocybin, recently shown to rapidly improve mood in
treatment-resistant depression (TRD), alters patients’ emo-
tional processing biases.
Methods Seventeen patients with treatment-resistant depres-
sion completed a dynamic emotional face recognition task at
baseline and 1 month later after two doses of psilocybin with
psychological support. Sixteen controls completed the emo-
tional recognition task over the same time frame but did not
receive psilocybin.
Results We found evidence for a group × time interaction on
speed of emotion recognition (p = .035). At baseline, patients
were slower at recognising facial emotions compared with
controls (p < .001). After psilocybin, this difference was
remediated (p = .208). Emotion recognition was faster at
follow-up compared with baseline in patients (p = .004,
d = .876) but not controls (p = .263, d = .302). In patients, this
change was significantly correlated with a reduction in anhe-
donia over the same time period (r = .640, p = .010).
Conclusions Psilocybin with psychological support appears
to improve processing of emotional faces in treatment-
resistant depression, and this correlates with reduced anhedo-
nia. Placebo-controlled studies are warranted to follow up
these preliminary findings.
Keywords Psilocybin . Emotional face recognition .
Treatment-resistant depression . Anhedonia
Introduction
Depressed patients exhibit negative affective biases in processing
static emotional face stimuli, and these are thought to contribute
to their low mood (Harmer et al. 2009). Selective serotonin or
noradrenaline reuptake inhibitors (SSRIs, SNRIs), such as
citalopram and reboxetine, respectively, have been shown to re-
mediate these negative affective biases in depressed patients
(Harmer et al. 2003a; Harmer et al. 2009). Also, in healthy vol-
unteers these drugs produce a bias towards happy faces, both
acutely and after 7 days’ administration (Harmer et al. 2003b;
Norbury et al. 2009). These neuropsychological changes are
thought to underlie the clinical effects of SSRIs and SNRIs
(Warren et al. 2015) and are predictive of clinical outcome
(Tranter et al. 2009; Shiroma et al. 2014).
In the real world, we process dynamic emotional expres-
sions, as opposed to the static faces referred to above (Platt
et al. 2010; Gepner et al. 2001; Robins et al. 2009). In an effort
to increase the ecological validity of emotional face recogni-
tion, some researchers have developed dynamically changing
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facial expression tasks (Joormann and Gotlib 2006; Platt et al.
2010). As with static faces, negative affective biases have
been observed in depressed patients with dynamic faces
(Münkler et al. 2015) and these abnormalities in dynamic
facial recognition are not evident in those who have responded
to antidepressant medication (Anderson et al. 2011).
Psilocybin is a mixed serotonin receptor agonist that has
displayed promising antidepressant potential (Carhart-Harris
et al. 2012a, 2016). In healthy volunteers, it acutely impaired
recognition of negative but not positive or neutral faces in the
‘Mind in the Eyes Task’ (Kometer et al. 2012) and increased
psychological and brain responses to positive autobiographi-
cal memories (Carhart-Harris et al. 2012b). Revising negative
cognitive and emotional biases in depression may be a viable
mechanism through which psilocybin acts to reduce depres-
sive symptoms (Harmer et al. 2017). However, to our knowl-
edge, no study has examined whether psilocybin can produce
longer-term changes in emotional face processing in people
with depression, and whether these are associated with chang-
es in depressive symptomology.
It is currently unclear why serotonergic drugs would act on
specific emotions over others and whether psilocybin’s effects
would differ from findings with SSRIs. Indeed, it has been
proposed that 5-hydroxytryptamine (5-HT) agonists, such as
psilocybin and SSRIs act via dissociable mechanisms—per-
haps due to the former having a preferential action at 5-HT2A
receptors and the latter, 5-HT1A receptors (Carhart-Harris and
Goodwin 2017; Carhart-Harris and Nutt 2017).
In this study, we used a dynamically changing facial ex-
pression task (DEER-T, Platt et al. 2010) to investigate the
impact of a psilocybin-based treatment on emotional process-
ing biases in depressed patients. These outcomes were com-
pared with test-retest data in a separate healthy control group.
Patients took part in a recently reported pilot study of psilocy-
bin (Carhart-Harris et al. 2016) and completed the task at pre-
treatment baseline and 1 week after treatment. Controls did
not take part in this trial but completed the task over a consis-
tent time period. Our primary hypothesis was that the de-
pressed patients’ would have impaired facial processing at
baseline compared with controls and treatment with psilocy-
bin would remediate this difference, as evidenced by a group
× time interaction for reaction time data. We also predicted
that this remediation effect would correlate with changes in
depressive symptoms.
Method
Participants
Patients with treatment-resistant depression took part in a pilot
study of psilocybin-based treatment. Findings have been re-
ported regarding a subset (n = 12) of these patients (Carhart-
Harris et al. 2016). Here, we present data from this initial
sample plus an additional five patients, all of whom completed
the DEER-T. Those with unipolar depression of at least mod-
erate severity (17+ on the 21 item HAM-D) and who had not
benefited from previous treatment with two antidepressant
medications taken for at least 6 weeks were included.
Seventeen of the 20 patients in the psilocybin depression
study completed the DEER-T, and their data are reported here.
For the purposes of this study, we additionally tested 16
healthy control participants twice over the same time period.
Inclusion criteria for controls were (1) normal or corrected to
normal vision, (2) able to complete computer tasks, (3) aged
18–60, and (4) fluent in English. Exclusion criteria were (1) a
clinically diagnosed psychiatric illness and (2) a clinically
diagnosed learning difficulty.
Procedure
Full details of the pilot study procedures have been reported
elsewhere (Carhart-Harris et al. 2016). Patients were screened
at the Imperial Clinical Research Facility (ICRF). This in-
volved informed consent, mental and physical health back-
ground documentation, the MINI-5 interview, physical exam-
ination, blood tests, ECG, urine test for drugs of abuse and
pregnancy and an alcohol breathalyser. At this point, they also
completed baseline measures including the 16-item Quick
Inventory of Depressive Symptoms (QIDS-16, Rush et al.
2003), the Snaith-Hamilton Pleasure Scale (SHAPS, Snaith
et al. 1995) and the Dynamic Emotional Expression
Recognition Task (DEER-T, Platt et al. 2010).
Eligible patients attended two dosing sessions, separat-
ed by 1 week. In the first session, patients received 10 mg
of psilocybin and in the second, they received 25 mg. The
low-dose session was planned a priori as a safety session
prior to a full-dose treatment session. This was included to
minimise the likelihood of an adverse reaction during the
high-dose session by familiarising patients with the study
procedures and some of the subjective effects of psilocy-
bin. The time point chosen to assess the efficacy of psilo-
cybin was 1 week after the high-dose session in order to
allow comparison with previous studies on ketamine in
treatment-resistant depression (e.g. Zarate et al. 2006).
Psychological support comprised of the following, which
can be summarised as preparation, (acute) support and
integration: (1) Preparation: Prior to dosing, patients
underwent an extensive preparatory session with their
assigned psychiatrist and clinical psychologist or counsellor.
This involved discussing their personal history (and depres-
sion), the subjective effects of psilocybin and an imitation of
features of the dosing session, such as listening to a portion of
the session music whilst wearing eyeshades. (2) (Acute)
support: The dosing sessions took place in a pre-decorated
room (e.g. low lighting, fabric drapes, flowers on bedside
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table) with two psychiatrists present. A non-directive, support-
ive approachwas adopted, with the aim of allowing the patient
an uninterrupted experience (Griffiths et al. 2016). Regular
check-ins (asking the patient how they were feeling) occurred
approximately every hour. (3) Integration: Patients met with
their therapy pair 1 day after the high-dose session and were
invited to talk through their experience. Compassionate listen-
ing and occasional interpretations were practised.
One week after the second treatment session (approximately
1 month after baseline), patients again returned to the ICRF for
further integrationwork and to complete theDEER-T, theQIDS-
16 and SHAPS. Controls did not take part in this trial but com-
pleted the task over a similar time period (1 month between ‘pre’
and ‘post’ time points). This was an opportunistic sample from
an open-label trial and therefore the sample size was not based
on a formal power calculation. Despite this, the sample size is
similar (n = 17) to that used by Kometer et al. (2012).
Dynamic Emotional Expression Recognition Task
Emotional processing was assessed with the DEER-T, which
is described in detail elsewhere (Platt et al. 2010). Static colour
photographs of six male and six female Caucasian actors were
taken from the NimStim Face Stimulus Set (Tottenham et al.
2009). These were morphed to create six dynamic emotional
stimuli expressing happiness, neutrality, sadness, anger, dis-
gust, or fear. Stimuli morphed from neutral to a full display of
an emotion over 3000 ms. There were six response buttons,
one for each of the emotions. Participants were asked to press
the key corresponding to the emotion becoming displayed as
quickly and accurately as possible. The primary variable of
interest is the reaction time on correct trials.
Questionnaires
At baseline and 1 week after the high (25 mg) psilocybin dose,
participants also completed the QIDS-16 (Rush et al. 2003) to
index depression and the SHAPS (Snaith et al. 1995) to index
lack of enjoyment of usually pleasurable activities. Controls
completed the QIDS-16 on the same session as the DEER-T
(pre and post) over the same time period.
Statistical analysis
Group differences in age were analysed using an independent
sample t test. Changes in SHAPS scores in patients were
analysed using a paired sample t test (pre, post). A 2 × 2 re-
peated measures ANOVAwas conducted on QIDS-16 scores
with time as the within-subject factor and group as the
between-subject factor. Reaction time, accuracy, sensitivity
(Pr) and response bias (Br) data on the DEER-Twere analysed
using a 2 × 6 × 2 mixed ANOVAwith time (pre and post) and
emotion type (happy, neutral, sad, angry, disgusted and
fearful) as within-subject factors and group (depressed pa-
tients and healthy controls) as the between-subject factor,
followed up by Bonferroni-corrected t tests to explore any
interactions. Cohen’s d (Cohen 1988) was calculated using
the formula described by Morris and DeShon (2002).
Missing data were handled using listwise deletion.
A two-high threshold model was used in order to calculate
participants’ sensitivities (Pr) and response biases (Br) in
recognising certain emotions (Snodgrass and Corwin 1988).
The two-high threshold measures (Pr and Br) were used as
non-parametric alternatives to signal detection measures (d’
and C) because accuracy data were not normally distributed.
Sensitivity (Pr) reflects the probability, under conditions of
uncertainty, that a certain emotional stimulus crosses a recog-
nition threshold (Kamboj et al. 2012; Hindocha et al. 2014).
Thus, the more sensitive one is to changes between emotions,
the larger the value of Pr. Pr is calculated by subtracting the
proportion of false alarms (p(FA): faces incorrectly identified
as a certain emotion) from the proportion of hits (p(HIT): faces
correctly identified as a certain emotion). Response bias (Br)
is calculated by dividing the proportion of false alarms by one
minus Pr (p(FA)/(1-Pr)). A larger Br value represents a more
liberal approach and a lower value indicates a more conserva-
tive approach towards recognising a certain emotion.
Results
Demographics and depressive symptoms (Table 1)
Controls (n = 11 males, n = 5 females) had no psychiatric
illness and were significantly younger (p = .002) with a mean
age of 32 (SD = 10.40) than the patient group (n = 11 males,
n = 6 females) with a mean age of 44.94 (SD = 11.51). All
patients had previously used at least two antidepressant medi-
cations, seven were currently using psychiatric medication and
withdrew or reduced these prior to dosing, all but two patients
had received some form of counselling or psychotherapy with
six receiving CBT and five patients also had a previous diag-
nosis of another psychiatric condition. Patient demographics
for a subset of this sample (n = 12) have been described in
more detail elsewhere (Carhart-Harris et al. 2016).
Table 1 Depressive symptoms for patients and controls at the ‘pre’ and
‘post’ time points
Patients Controls
Pre Post Pre Post
QIDS-16 18.88 (2.23) 7.65 (5.34) 4.13 (3.90) 4.13 (3.32)
SHAPS 6.82 (4.02) 1.47 (2.43) – –
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In patients, SHAPS scores were significantly reduced at the
‘post’ treatment time point as compared to the ‘pre’ treatment
time point, indicating an improved capacity for experiencing
pleasure following psilocybin-based treatment (F (1,
16) = 37.14, p < .001, ηp
2 = .699). For QIDS-16 scores, there
was a significant interaction effect of time and group (F (1,
31) = 68.18, p < .001, ηp
2 = .687). There were main effects of
time (F (1, 31) = 68.18, p < .001, ηp
2 = .687) and group (F (1,
31) = 61.63, p < .001, ηp
2 = .665). Bonferroni-corrected pair-
wise t tests (α = .025) revealed that the QIDS-16 scores for
patients were significantly lower (p < .001) at the ‘post’ time
point (M = 7.65, SD = 5.34) as compared to the ‘pre’ time point
(M = 18.88, SD = 2.23), reflecting a reduction in depressive
symptoms following psilocybin-based treatment. No significant
difference in QIDS-16 scores was observed for controls be-
tween the ‘pre’ and ‘post’ time points (p = 1.00). These findings
have been presented elsewhere (Carhart-Harris et al. 2016).
Dynamic Emotional Expression Recognition Task
Reaction time There were significant interaction effects be-
tween time and group (F (1, 28) = 4.91 p = .035, η2 = .149) time
and emotion (F (5, 140) = 2.67, p= .025, ηp
2 = .087) and emotion
and group (F (5, 140) = 2.56, p = .030, ηp
2 = .084). There were
also significant main effects of time (F (1, 28) = 12.10, p = .002,
ηp
2 = .302), group (F (1, 28) = 11.02, p = .003, ηp
2 = .282) and
emotion (F (5, 140) = 78.23, p < .001, ηp
2 = .736).
Bonferroni-corrected pair-wise t tests (α = .0125) to exam-
ine the time by group interaction revealed that the reaction
time across all emotions for patients was significantly faster
(p = .004, d = .876) at the ‘post’ time point (M = 2015.48,
SE = 38.84) as compared with the ‘pre’ time point
(M = 2192.58, SE = 34.38), whereas the reaction time for
controls was not significantly different (p = .263, d = .302)
across the two time points (Fig. 1). Moreover, controls were
significantly faster than patients at the ‘pre’ time point
(p < .001) but at the ‘post’ time point, there was no significant
difference between the two groups (p = .208).
Bonferroni-corrected pair-wise t tests (α = .008) to ex-
amine the time by emotion interaction revealed that the
reaction time in both groups combined for angry
(M = 2006.86, SE = 36.26) faces at the ‘post’ time point
was significantly faster (p = .001) as compared with angry
(M = 2147.25, SE = 43.31) faces at the ‘pre’ time point.
There were no significant differences in reaction time
across both groups between ‘pre’ and ‘post’ for the other
emotions.
Bonferroni-corrected pair-wise t tests (α = .008) to ex-
amine the emotion by group interaction revealed that reac-
tion times were significantly faster in the control group for
neutral (p = .003), angry (p < .001), disgusted (p = .001)
and fearful (p = .001) faces as compared with the patient
group. Means and standard errors are reported in
Online Resource 3. There was no significant interaction
of emotion, group and time (F (5, 140) = .993, p = .424,
ηp
2 = .034).
Accuracy There was a significant interaction effect of emo-
tion and group (F (5, 27) = 3.75, p = .009, ηp
2 = .108). There
were also significant main effects of time (F (1, 31) = 12.5,
p = .001, ηp
2 = .287) and emotion (F (3.63, 112) = 35.44,
p < .001, ηp
2 = .533) but not group (p = .119). Bonferroni-
corrected (α = .008) independent sample t tests to examine the
emotion by group interaction showed that across both time
points, controls were significantly more accurate (p < .001)
when responding to angry faces (M = .8930, SE = .018) as
compared with patients (M = .7479, SE = .03). There were no
significant differences between groups on the other emotions.
There were no significant interactions of time and group
(p = .124), time and emotion (p = .057), or emotion, group
and time (p = .240).
Fig. 1 Mean reaction time to correctly respond to all emotions on the
DEER-T task in patients and controls. Patients were significantly faster at
the ‘post’ time point as compared with the ‘pre’ time point (p = .004).
Reaction time for controls was not significantly different between the two
time points (p = .263). Controls were significantly faster than patients at
the ‘pre’ time point (p < .001) but at the ‘post’ time point there was no
significant difference between the two groups (p = .208). Error bars are
± 1 SE and * denotes a p value < .0125
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Discrimination There was a significant interaction effect of
emotion and group (F (3.72, 115) = 2.95, p = .026, ηp
2 = .087).
There were also significant main effects of time (F (1,
31) = 9.97, p = .004, ηp
2 = .243) and emotion (F (3.72,
115) = 34.69, p < .001, ηp
2 = .528) but not group (p = .197).
Bonferroni-corrected (α = .008) independent sample t tests to
examine the emotion by group interaction showed that sensi-
tivity (Pr) across both time points was significantly higher for
angry faces (p = .002) in controls (M = .831, SE = .168) as
compared with patients (M = .717, SE = .032). There were no
significant interactions of time and emotion (F (3.36,
104) = 1.77, p = .152, ηp
2 = .054) or time and group (F (1,
31) = 2.18, p = .150, ηp
2 = .066) or time, group and emotion (F
(3.36, 104) = 1.66, p = .149, ηp
2 = .051).
Response bias There were significant interaction effects of
time and emotion (F (3.26, 101) = 4.45, p = .004,
ηp
2 = .126) and emotion and group (F (3.54, 110) = 7.04,
p < .001, ηp
2 = .185). There were also significant main effects
of time (F (1, 31) = 4.86, p = .035, ηp
2 = .136), emotion (F
(3.54, 110) = 27.57, p < .001, ηp
2 = .471) and group (F (1,
31) = 18.71, p < .001, ηp
2 = .376). Bonferroni-corrected
(α = .008) paired sample t tests to examine the time by emo-
tion interaction showed that across both groups, there was a
significantly more liberal response bias (p = .001) towards
neutral faces at the ‘post’ time point (M = .255, SE = .033)
as compared to the ‘pre’ time point (M = .148, SE = .025).
Response bias for other emotions across both groups did not
significantly differ from the ‘pre’ time point to the ‘post’ time
point. Bonferroni-corrected (α = .008) independent sample t
tests to examine the emotion by group interaction showed that
across both time points, there was a significantly more liberal
response bias towards angry faces (p < .001) in controls
(M = .35, SE = .036) as compared with patients (M = .128,
SE = .017). No significant group differences in response bias
(Br) were found for the other emotions across both time
points. There were no significant interaction effects of time
and group (p = .711) or emotion, group and time (p = .867).
Correlations Given that patients showed a reduction in reac-
tion time for all emotions, and improved symptomology on
the QIDS-16 and SHAPS, correlations were conducted be-
tween change scores on these variables in the patient group.
A significant positive correlation was observed between
change in reaction time across all emotions and change in
SHAPS score in patients (r = .640, p = .010, Fig. 2). This
indicates that faster identification of emotional expressions
was associated with reduced anhedonia in patients. This rela-
tionship appeared to be relatively selective to this particular
depressive symptom, as QIDS-16 score change was not sig-
nificantly correlated with reaction time change in patients
(r = − .073, p = .796). Because age significantly differed
between patients and controls, we explored correlations
between age and reaction time to respond to all emotions.
We found no evidence for an association in patients
(r = − .299, p = .278) or controls (r = .375, p = .169). There
was also no evidence for an association between change in
reaction time to respond to all emotions and age in patients
(r = .106, p = .707) or controls (r = .196, p = .484) or in both
groups combined (r = − .099, p = .603).
Discussion
Patients treated with psilocybin with psychological support
for treatment-resistant depression and a group of healthy con-
trols receiving no treatment carried out a dynamic emotional
faces task at two time points, separated by approximately
1month. Prior to treatment with psilocybin, depressed patients
in this trial were shown to have a global deficit in processing
emotional faces as compared with healthy controls, as
reflected in longer reaction times to identify all emotion types.
Post-treatment, this between-group difference was
remediated—with patients performing as well as controls.
We observed a reaction time improvement post-treatment for
all emotion types in depressed patients. In the control group,
who were not given psilocybin, no retest improvement was
observed. This suggests the improvement in the depressed
group is not due to a learning effect but rather, may be related
to their treatment.
We observed a significant positive correlation between
faster RT to all emotions and improvements in anhedonia
scores post-treatment. Anhedonia (lack of pleasure or interest
in normally rewarding activities) is a key component of de-
pression—and yet it is relatively unresponsive to standard
antidepressant treatments (Lally et al. 2014). Both psilocybin
with psychological support (Carhart-Harris et al. 2016) and
ketamine (Lally et al. 2014) appear to facilitate an immediate
improvement in anhedonia in depression. It has been
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Fig. 2 Change in reaction time to all emotions correlated with change in
SHAPS score in depressed patients receiving psilocybin-based treatment
(r = .640, p = .010). The larger the decrease in reaction time to detect
emotional faces, the larger the reduction in anhedonia
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suggested that ketamine’s fast-acting antidepressant effect
may be due to large and immediate neurocognitive changes
(Warren et al. 2015; Deakin et al. 2012; Abel et al. 2003) that
subsequently allow fast relearning of patients’ social environ-
ments (Pringle et al. 2013). Our observed correlation suggests
that improvements in facial processing relate to contempora-
neous improvements in symptoms of anhedonia, in line with
the neurocognitive model of antidepressant action (Warren
et al. 2015). No correlations were observed between facial
processing performance and the study’s primary measure of
depressive symptoms (QIDS-16), suggesting that the post-
treatment changes in emotional processing are selective to
the symptom of anhedonia.
It has been recently proposed that psilocybin activates an
emotion-releasing pathway mediated via the 5-HT2A receptor
whilst SSRIs act on an emotion-moderating pathway mediated
by postsynaptic 5-HT1AR signalling (Carhart-Harris and
Goodwin 2017, Carhart-Harris and Nutt 2017). SSRIs have
been associated with emotional moderation or ‘blunting’
(Price et al. 2009), whilst 15 out of 20 patients in the current
trial endorsed a theme antithetical to this, labelled ‘emotional
reconnection’ and ‘acceptance’ (Watts et al. 2017).
Speculatively, the improved processing of all emotions, includ-
ing negative ones, seen here post-treatment with psilocybin
could be interpreted as consistent with emotional reconnection
(Watts et al. 2017; Carhart-Harris et al. 2017). Indeed, recent
research using the same sample as the current study with an
additional two patients (n = 19) has shown increased amygdala
response to fearful faces as compared with neutral faces after
psilocybin (Roseman et al. 2017, Neuropsychopharmacology,
under review). Reconnecting with one’s emotions and environ-
ment could account for the inter-related improvements in anhe-
donia and emotional processing post-psilocybin.
Focusing on group differences irrespective of treatment, an
emotion × group interaction effect was observed, where across
both time points combined, controls were faster at responding
to neutral, angry, disgusted and fearful faces as compared with
the depressed group. This finding is broadly consistent with
the findings of Dalili et al.’s (2015) meta-analysis of 22 emo-
tional face processing studies, which concluded that there was
a global deficit for all basic emotions (anger, disgust, fear,
happiness and surprise) except sadness in those with depres-
sion (Dalili et al. 2015). A key limitation here is that no three-
way interaction was observed; thus, any interpretation of
emotion-specific deficits across group and time should be
treated with caution. Moreover, although age did not correlate
with task performance, the two groups differed in age.
We also observed a time by emotion interaction effect, where
reaction time for angry faces in both groups combined was sig-
nificantly faster at the ‘post’ time point. This may reflect a
differential learning effect on angry faces in this task that is
insensitive to group, as we did not see a significant interaction
with group on this measure.
There was a significant emotion by group interaction effect
where across both time points combined, controls were more
accurate at identifying angry faces. This was also reflected in a
higher discrimination index (Pr) and amove to the ideal response
bias (Br = 0.5) for angry faces in controls across both time points
combined as compared to patients. This may reflect the fact that
the emotional processing deficit in patients towards angry faces
is resilient to change post-psilocybin. Although it should be
noted that in this task, the faces become increasingly intense over
time and thus easier to answer correctly. Indeed, following pre-
vious use of this task (Platt et al. 2010) reaction time should be
the principal measurement from which to make conclusions.
In addition to emotional processing aptitude, performance
on facial recognition tasks also involves a variety of cognitive
functions such as selective attention, working memory and
visual perception (Stuhrmann et al. 2011). Depressed patients
are known to show cognitive impairments including both
mnemonic and executive impairments (Austin et al. 2001) as
well as perceptual deficits (Bschor et al. 2004; Bubl et al.
2010). Bearing this in mind, whether the depressed patients
in our study showed a specific improvement in emotional
processing or a more general cognitive improvement (e.g.
executive function) or even perceptual (e.g. contrast sensitiv-
ity) ability remains to be resolved. To do so would require the
inclusion of other behavioural paradigms in the trial, probing
different aspects of affective and cognitive processing. In the
future, it would be valuable to include other cognitive and
perceptual tasks, in order to test whether psilocybin-
treatment has a selective influence on emotional face process-
ing or a more generalised remediating effect on affective and
cognitive processing.
Strengths of the present study include its focus on a novel
pharmacological mechanism associated with rapid improve-
ment in treatment-resistant depression, pre/post-assessments
in patients and controls, and a previously validated emotional
processing task based on dynamic face morphing. There are
several limitations to this study however, namely (1) controls
were significantly younger than the patients and age has been
found to affect emotional face recognition (Leime et al. 2013),
(2) controls did not undergo a placebo treatment as they would
in a randomised control trial (RCT), (3) additional cognitive
tasks were not administered, (4) the sample size was modest,
(5) SHAPS was not collected in controls and (6) the treatment
group had psilocybin and psychological support whilst the
control group had neither. There is some evidence that extend-
ed psychological intervention (16 sessions) may influence
processing of facial affect in depression (Fu et al. 2008).
Future studies should aim to determine whether psychological
support and psilocybin have additive or synergistic effects on
depressive symptoms and emotion recognition (Moss et al.
2016). Bearing in mind the ethical concerns of a psilocybin-
only group in people with depression, this may be best
achieved by comparing a minimum level of support with
Psychopharmacology
increasing doses of psychological intervention. In the future,
studies could also incorporate an eye-tracking paradigm, as an
intriguing explanation for reduced performance on emotional
face recognition tasks may be aversion of gaze away from
emotional stimuli. Many of these limitations were standard
for an open-label pilot study such as it was, and can be ad-
dressed properly in future RCTs.
In conclusion, this study found generalised improvements
in emotional face processing after psilocybin for treatment-
resistant major depression that correlated with reduced anhe-
donia. Further studies are required to help determine whether
the observed improvements are specific to emotion process-
ing or more generalised, i.e. including improvements in per-
ception and/or cognition; if the former, it will be important
to address whether improvements in emotional processing
are an integral component of the antidepressant mechanisms
of this novel treatment modality (Carhart-Harris and
Goodwin 2017).
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